statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462...

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity

Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program...

Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will...

Tango Therapeutics Announces Discontinuation of TNG348 Program

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial...

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Cantor Fitzgerald initiated coverage on shares of Tango Therapeutics (NASDAQ:TNGX - Free Report) in a research note issued to investors on Thursday morning, MarketBeat Ratings reports. The firm...

Tango Therapeutics (NASDAQ:TNGX) Now Covered by Cantor Fitzgerald

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tango Therapeutics initiated with bullish view at Cantor Fitzgerald

This is a signal that TNGX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Tango Therapeutics (TNGX, $7.65) RSI Indicator left the oversold zone on April 01, 2024

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that...

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics (TNGX, $7.95) RSI Indicator left the oversold zone on March 28, 2024

In trading on Friday, shares of Tango Therapeutics Inc (TNGX) crossed below their 200 day moving average of 8.04, changing hands as low as 7.75 per share. Tango Therapeutics Inc shares are...

Tango Therapeutics Breaks Below 200-Day Moving Average - Notable for TNGX

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Watchers	334
52-Wk Low	$2.47
52-Wk High	$13.03

Volume	566,383.00
52-Wk High	$13.03
52-Wk Low	$2.47

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.34	--	--	N/A
Q1'24	-$0.31	-$0.35	-12.90%	MISSED
Q4'23	-$0.27	-$0.32	-16.79%	MISSED
Q3'23	-$0.34	-$0.23	31.75%	BEAT
Q2'23	-$0.33	-$0.23	29.45%	BEAT

TNGX Tango Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals